Pamela Valentine's lobbying: the registrations they file and every meeting they've reported since November 2021.
← LobbyingRegistrant (responsible officer)
President & CEO
For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.
Registered since Aug 24, 2026
Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.
We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.
We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Employment Insurance sickness benefits, with respect to creation of flexible benefits for persons with MS and other episodic disabilities
We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
Comprehensive disability income programs, with respect to persons with MS and other chronic and episodic disabilities
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
CIHR as it relates to federal funding & long term investment in health research
Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.
Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Employment Insurance sickness benefits, with respect to creation of flexible benefits for persons with MS and other episodic disabilities
Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Canada Health Act and regulations, as it relates to long-term and home care
Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Comprehensive disability income programs, with respect to persons with MS and other chronic and episodic disabilities
Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.
Home care, with respect to creation with provincial/ territorial governments programs relating to increased home care for persons with MS and other disabilities/ diseases and the support of caregivers
We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.
Canada Health Act and regulations, as it relates to long-term and home care
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.
Home care, with respect to creation with provincial/ territorial governments programs relating to increased home care for persons with MS and other disabilities/ diseases and the support of caregivers
Employment Insurance sickness benefits, with respect to creation of flexible benefits for persons with MS and other episodic disabilities
We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
Canada Pension Plan – Disability with respect to eligibility for persons with MS and other chronic and episodic disabilities
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Safe Long-Term Care Act with respect to persons affected by MS
Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.
Canada Pension Plan – Disability with respect to eligibility for persons with MS and other chronic and episodic disabilities
Comprehensive disability income programs, with respect to persons with MS and other chronic and episodic disabilities
Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.
We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
Home care, with respect to creation with provincial/ territorial governments programs relating to increased home care for persons with MS and other disabilities/ diseases and the support of caregivers
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Bill C-64, An Act Respecting Pharmacare with respect for persons with MS and other chronic conditions and disabilities
Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.
Canada Health Act and regulations, as it relates to long-term and home care
Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.
Canada Health Act and regulations, as it relates to long-term and home care
Canada Disability Benefit Regulations, with respect to creating a benefit that can be accessed by Canadians with episodic disabilities and lifts Canadians with disabilities out of poverty
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Canada Pension Plan – Disability with respect to eligibility for persons with MS and other chronic and episodic disabilities
Comprehensive disability income programs, with respect to persons with MS and other chronic and episodic disabilities
Canada Pension Plan – Disability with respect to eligibility for persons with MS and other chronic and episodic disabilities
Canada Disability Benefit Regulations, with respect to creating a benefit that can be accessed by Canadians with episodic disabilities and lifts Canadians with disabilities out of poverty
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Canada Disability Benefit Regulations, with respect to creating a benefit that can be accessed by Canadians with episodic disabilities and lifts Canadians with disabilities out of poverty
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities
Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.